

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>AVITA Therapeutics, Inc. ("Avita US")</b>
<b>ARBN</b>	<b>641 288 155</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael Perry
<b>Date of last notice</b>	30 June 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
<b>Date of change</b>	9 September 2020, 10 September 2020 and 12 September 2020 (Pacific Time)

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p>1,266,125 CHESS Depositary Interests (“CDIs”) in Avita US (representing beneficial ownership in 253,225 shares of common stock in Avita US).</p> <p>Mr Perry also held the following convertible securities in AVITA Medical Limited ACN 28 058 466 523 (“<b>Avita Australia</b>”), being a wholly owned subsidiary of Avita US, prior to the change:</p> <ul style="list-style-type: none"> <li>• 15,000,000 unquoted options; and</li> <li>• 29,435,917 unquoted restricted stock units (“RSUs”).</li> </ul> <p>The convertible securities held in Avita Australia entitle Mr Perry, upon vesting of their conversion rights, to be issued shares of common stock in Avita US (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in Avita US’s pre-quotations disclosure released to the market on 24 June 2020.</p>
<b>Class</b>	As above
<b>Number acquired</b>	83,333 shares of common stock in Avita US (which do not presently have CDIs issued over them and therefore are not quoted on ASX) acquired on 9 September 2020 (Pacific Time).
<b>Number disposed</b>	<p>8,333,334 unquoted RSUs in Avita Australia (consolidation equivalent = 83,333 unquoted RSUs in Avita US) which were converted into 83,333 shares of common stock in Avita US that were issued on 9 September 2020 (Pacific Time).</p> <p>27,128 shares of common stock in Avita US were subsequently disposed of on 10 and 11 September 2020 (Pacific Time).</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Acquisition of 83,333 shares of common stock in Avita US - nil consideration (issued as a result of the vesting of the relevant tranche of Mr Perry's unquoted RSUs in Avita Australia).</p> <p>Disposal of 27,128 shares of common stock in Avita US – US\$26.08 per share of common stock (being the average price per share of common stock sold).</p>
<b>No. of securities held after change</b>	<p>1,266,125 CDIs in Avita US quoted on ASX (representing beneficial ownership in 253,225 shares of common stock in Avita US).</p> <p>56,205 shares of common stock in Avita US quoted on the NASDAQ Stock Market LLC.</p> <p>15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in Avita US).</p> <p>21,102,583 unquoted RSUs in Avita Australia (consolidation equivalent = 211,026 unquoted RSUs in Avita US).</p> <p>The convertible securities held in Avita Australia entitle Mr Perry, upon vesting of their conversion rights, to be issued shares of common stock in Avita US (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in Avita US's pre-quotations disclosure released to the market on 24 June 2020.</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>Acquisition - Conversion of unquoted RSUs in Avita Australia.</p> <p>Disposal – On market sale</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y  
Change of Director's Interest Notice

---

<b>Name of registered holder (if issued securities)</b>	Not applicable
<b>Date of change</b>	Not applicable
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Not applicable
<b>Interest acquired</b>	Not applicable
<b>Interest disposed</b>	Not applicable
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Not applicable
<b>Interest after change</b>	Not applicable

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

---

<sup>+</sup> See chapter 19 for defined terms.